Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study
Nan‐Lin Wu, Chih‐Jung Hsu, Fang‐Ju Sun, et al.
The Journal of Dermatology (2017) Vol. 44, Iss. 10, pp. 1129-1137
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
Richard B. Warren, Andrew Blauvelt, Yves Poulin, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 1, pp. 50-59
Open Access | Times Cited: 159
Psoriasis in People With Skin of Color: An Evidence‐Based Update
Maria‐Angeliki Gkini, Mio Nakamura, Andrew Alexis, et al.
International Journal of Dermatology (2025)
Open Access | Times Cited: 3
Skin changes in the obese patient
Penelope A. Hirt, David Castillo, Gil Yosipovitch, et al.
Journal of the American Academy of Dermatology (2019) Vol. 81, Iss. 5, pp. 1037-1057
Closed Access | Times Cited: 142
Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups
Bridget Kaufman, Andrew Alexis
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 405-423
Closed Access | Times Cited: 109
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
Xiaoying Sun, Ziyang Cui, Qingyun Wang, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 4, pp. 103530-103530
Closed Access | Times Cited: 11
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis
Kazuhisa Furue, Takamichi Ito, Masutaka Furue
Cytokine (2018) Vol. 111, pp. 182-188
Closed Access | Times Cited: 72
Psoriasis and the TNF/IL23/IL17 axis
Kazuhisa Furue, Takamichi Ito, Gaku Tsuji, et al.
Giornale Italiano di Dermatologia e Venereologia (2019) Vol. 154, Iss. 4
Closed Access | Times Cited: 64
Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
Jiao Wang, Chunxiao Wang, Liu Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
Tzong-Yun Ger, Yu‐Huei Huang, Rosaline Chung‐Yee Hui, et al.
Therapeutic Advances in Chronic Disease (2019) Vol. 10
Open Access | Times Cited: 44
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
Lin Cai, Congjun Jiang, Guoqiang Zhang, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 3, pp. 336-343
Closed Access | Times Cited: 5
Crosstalk Among Circadian Rhythm, Obesity and Allergy
Kanami Orihara, Atsushi Haraguchi, Shigenobu Shibata
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1884-1884
Open Access | Times Cited: 29
Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review
Jessica E. Ferguson, Edward W. Seger, Jacob White, et al.
Archives of Dermatological Research (2022) Vol. 315, Iss. 1, pp. 41-50
Closed Access | Times Cited: 19
Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis
Yuting Xia, Jiajia Lan, Jing Yang, et al.
Cellular and Molecular Immunology (2025)
Closed Access
Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
Amy McMichael, Seemal R. Desai, Aamir Qureshi, et al.
American Journal of Clinical Dermatology (2018) Vol. 20, Iss. 2, pp. 267-276
Closed Access | Times Cited: 30
Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
Yi‐Wei Huang, Tsen‐Fang Tsai
Dermatology and Therapy (2019) Vol. 9, Iss. 3, pp. 553-569
Open Access | Times Cited: 29
Treatment Strategies for Psoriasis using Flavonoids from Traditional Chinese Medicine
Akash Gupta, Parag Jain, Kushagra Nagori, et al.
Pharmacological Research - Modern Chinese Medicine (2024) Vol. 12, pp. 100463-100463
Open Access | Times Cited: 3
The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies
Chen‐Yu Wu, Hsien‐Yi Chiu, Tsen‐Fang Tsai
PLoS ONE (2019) Vol. 14, Iss. 12, pp. e0225112-e0225112
Open Access | Times Cited: 22
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions
Kevin C.‐W. Wu, Michael P. Lee, Erica B. Lee, et al.
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 4, pp. 359-365
Closed Access | Times Cited: 21
Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
Yuliya Lytvyn, Muskaan Sachdeva, Asfandyar Mufti, et al.
Drugs in Context (2022) Vol. 11, pp. 1-12
Open Access | Times Cited: 11
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study
Min‐Geol Lee, Yu‐Huei Huang, Joo‐Heung Lee, et al.
The Journal of Dermatology (2019) Vol. 46, Iss. 9, pp. 752-758
Closed Access | Times Cited: 16
Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis
James Cheng‐Chung Wei, Chin‐Hsiu Liu, Jui‐Cheng Tseng, et al.
International Journal of Rheumatic Diseases (2019) Vol. 23, Iss. 1, pp. 7-23
Open Access | Times Cited: 16
Risk for Deep Fungal Infections During IL-17 and IL-23 Inhibitor Therapy for Psoriasis
Michael P. Lee, Kevin C.‐W. Wu, Erica B. Lee, et al.
Cutis (2020) Vol. 106, Iss. 4
Open Access | Times Cited: 15
Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich, Michael Song, Shu Li, et al.
The Journal of Dermatology (2019) Vol. 46, Iss. 12, pp. 1141-1152
Open Access | Times Cited: 12
Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis
Danyi Zhang, Jianing Qiu, Xing Liao, et al.
Frontiers in Medicine (2022) Vol. 8
Open Access | Times Cited: 6
Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study
Yangfeng Ding, Wei Li, Xin Guan, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 10, pp. 1803-1814
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top